Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $86

Wells Fargo analyst Derek Archila has maintained an Overweight rating on Disc Medicine (NASDAQ: IRON) and raised the price target from $79 to $86. This adjustment reflects a positive outlook for the company's performance in the market.